SpePharm Holding BV – the specialty pharmaceutical company dedicated to the sales and marketing of innovative hospital and specialists products throughout Europe – today announced the granting of national approvals of Loramyc in the UK, Denmark, Germany, Belgium, The Netherlands, Luxembourg, Finland and Sweden, as well as in Spain under the trade name Sitamic.
Loramyc 50mg, a mucoadhesive buccal tablet of miconazole, is indicated for the treatment of oropharyngeal candidiasis (OPC) in immuno-compromised patients. At the same time, Loramyc has been launched in the UK and will be promoted in the secondary care setting mostly to cancer and HIV/AIDS patients suffering from OPC.
Jean-François Labbé, President and CEO of SpePharm said: “Following marketing approval and this initial launch in the UK, further launches of Loramyc will follow as other national marketing authorisations are granted, and SpePharm continues to aggressively put in place its sales and marketing infrastructure throughout Europe”.
Mike Stowe, SpePharm UK Ltd Managing Director added: “We all feel very positive about the UK launch of Loramyc as the initial feedback from specialists indicates a real need for this product due to the lack of optimal efficacy and compliance issues with currently available products.
“Although guidelines recommend the first line use of a topical buccal treatment for OPC, in many cases specialists are being forced to move immediately to systemic drugs with the attendant risks of generating both resistance and potentially severe drug-drug interactions. We believe that Loramyc is the only topical, once-daily, effective treatment for OPC in this important group of immuno-compromised patients.”